Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome

JAMA Dermatology

Volumn 151, Issue 1, 2015, Pages 73-77

  Mehra, Tarun ^a   Ikenberg, Kristian ^a   Moos, Rudolf Maria ^a   Benz, Rudolf ^b   Nair, Gayathri ^a   Schanz, Urs ^a   Haralambieva, Eugenia ^a   Hoetzenecker, Wolfram ^c   Dummer, Reinhard ^c   French, Lars Einar ^c   Guenova, Emmanuella ^c   Cozzio, Antonio ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Kantonsspital Muensterlingen   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; BEXAROTENE; BRENTUXIMAB VEDOTIN; BUSULFAN; CD30 ANTIGEN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; FORODESINE; GEMCITABINE; METHOTREXATE; PACLITAXEL; PREDNISONE; THYMOCYTE ANTIBODY; VINCRISTINE SULFATE; VORINOSTAT; ANTIBODY CONJUGATE; CAC10-VCMMAE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CD30+ T LYMPHOCYTE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; PUVA; SEZARY SYNDROME; T LYMPHOCYTE; TIME TO TREATMENT; TREATMENT DURATION; TUMOR VOLUME; ULTRAVIOLET B RADIATION; ALLOTRANSPLANTATION; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; PROGNOSIS; SKIN NEOPLASMS; STEM CELL TRANSPLANTATION;

ADULT; AGED; ANTIGENS, CD30; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOCONJUGATES; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; PROGNOSIS; SEZARY SYNDROME; SKIN NEOPLASMS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84921342421     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2014.1629     Document Type: Article

References (14)

1. Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome), part II: prognosis, management, and future directions. J Am Acad Dermatol. 2014;70(2):223.e1-223.e17.
2. Talpur R, Singh L, Daulat S, et al. Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res. 2012;18(18):5051-5060.
3. Benner MF, Jansen PM, Vermeer MH, Willemze R. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood. 2012;119(7):1643-1649.
4. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190-2196.
5. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183-2189.
6. Dummer R, Quaglino P, Becker JC, et al. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advancedmycosis fungoides: final results from EORTC 21012. J Clin Oncol. 2012;30(33):4091-4097.
7. Benton EC, Crichton S, Talpur R, et al. A cutaneous lymphoma international prognostic index (CLIPi) formycosis fungoides and Sezary syndrome. Eur J Cancer. 2013;49(13):2859-2868.
8. Dummer R, Rozati S, Guenova E, Cozzio A. Less can be more: the impact of chemotherapy on cutaneous T-cell lymphomas. Future Oncol. 2013;9(8):1061-1064.
9. Guenova E, Hoetzenecker W, Rozati S, Levesque MP, Dummer R, Cozzio A. Novel therapies for cutaneous T-cell lymphoma: what does the future hold? Expert Opin Investig Drugs. 2014;23(4):457-467.
10. Duvic M, Tetzlaff M, Gangar P, Clos A, Talpur R. Phase II trial of brentuximab vedotin (SGN-35) for CD30+ cutaneous T-cell lymphomas and lymphoproliferative disorders. J Invest Dermatol. 2013;133(suppl 1s):180.
11. Corey K, Cook D, Bekker J, Mugnaini E, Lin JH. A case of refractory Sézary syndrome with large-cell transformation responsive to brentuximab vedotin. JAMA Dermatol. 2014;150(2):210-212.
12. Suga H, Sugaya M, Miyagaki T, et al. Differential patterns of CXCR3, CCR3, and CCR10 expression in mycosis fungoides, Sezary syndrome and CD30(+) lymphoproliferative disorders: immunohistochemical study of 43 samples. J Dermatol Sci. 2011;64(2):142-144.
13. Gopal AK, Ramchandren R, O'Connor OA, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012;120(3):560-568.
14. Theurich S, Malcher J, Wennhold K, et al. Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission. J Clin Oncol. 2013;31(5):e59-e63.